James I. Healy, M.D., Ph.D. has been a member of our Board of Directors since February 2014.
Dr. Healy has been a General Partner of Sofinnova Ventures, a venture capital firm, since June 2000. Prior to June 2000, Dr. Healy held various positions at Sanderling Ventures, Bayer Healthcare Pharmaceuticals (as successor to Miles Laboratories) and ISTA Pharmaceuticals, Inc. Dr. Healy is currently on the board of directors of Ascendis Pharma, Bolt Biotherapeutics, Natera, Karuna Therapeutics, NuCana plc, and Y-mAbs Therapeutics, and is a board observer at Visen. Previously, he served as a board member of InterMune, Inc., Amarin Corp., Auris Medical, Hyperion Therapeutics, Inc., Anthera Pharmaceuticals, Inc., Durata Therapeutics, Inc., CoTherix, Inc., Movetis NV and several private companies.
Dr. Healy holds an M.D. and a Ph.D. in Immunology from the Stanford University School of Medicine, a B.A. in Molecular Biology and a B.A. in Scandinavian Studies from the University of California, Berkeley.
What is James I. Healy's net worth?
The estimated net worth of James I. Healy is at least $100,944.04 as of December 13th, 2023. Dr. Healy owns 42,236 shares of Coherus BioSciences stock worth more than $100,944 as of March 29th. This net worth estimate does not reflect any other investments that Dr. Healy may own. Learn More about James I. Healy's net worth.
How do I contact James I. Healy?
Has James I. Healy been buying or selling shares of Coherus BioSciences?
James I. Healy has not been actively trading shares of Coherus BioSciences over the course of the past ninety days. Most recently, James Healy sold 286,076 shares of the business's stock in a transaction on Wednesday, September 29th. The shares were sold at an average price of $16.12, for a transaction totalling $4,611,545.12. Learn More on James I. Healy's trading history.
Who are Coherus BioSciences' active insiders?
Are insiders buying or selling shares of Coherus BioSciences?
In the last twelve months, insiders at the biotechnology company sold shares 1 times. They sold a total of 223,100 shares worth more than $450,662.00. The most recent insider tranaction occured on November, 22nd when CEO Dennis M Lanfear sold 223,100 shares worth more than $450,662.00. Insiders at Coherus BioSciences own 11.0% of the company.
Learn More about insider trades at Coherus BioSciences. Information on this page was last updated on 11/22/2023.